- Home
- ELWS vs INAB Comparison
ELWS vs INAB Comparison
Compare ELWS & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- INAB
- Stock Information
- Founded
- ELWS 2018
- INAB 2016
- Country
- ELWS Japan
- INAB United States
- Employees
- ELWS N/A
- INAB N/A
- Industry
- ELWS
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- INAB Health Care
- Exchange
- ELWS Nasdaq
- INAB Nasdaq
- Market Cap
- ELWS 12.1M
- INAB 10.8M
- IPO Year
- ELWS 2023
- INAB 2021
- Fundamental
- Price
- ELWS $3.19
- INAB $2.35
- Analyst Decision
- ELWS
- INAB Strong Buy
- Analyst Count
- ELWS 0
- INAB 2
- Target Price
- ELWS N/A
- INAB $108.00
- AVG Volume (30 Days)
- ELWS 182.1K
- INAB 84.2K
- Earning Date
- ELWS 09-30-2025
- INAB 11-11-2025
- Dividend Yield
- ELWS N/A
- INAB N/A
- EPS Growth
- ELWS N/A
- INAB N/A
- EPS
- ELWS N/A
- INAB N/A
- Revenue
- ELWS $3,083,071.00
- INAB N/A
- Revenue This Year
- ELWS N/A
- INAB N/A
- Revenue Next Year
- ELWS N/A
- INAB N/A
- P/E Ratio
- ELWS N/A
- INAB N/A
- Revenue Growth
- ELWS 145.52
- INAB N/A
- 52 Week Low
- ELWS $1.64
- INAB $1.91
- 52 Week High
- ELWS $10.50
- INAB $16.70
- Technical
- Relative Strength Index (RSI)
- ELWS 56.54
- INAB 64.40
- Support Level
- ELWS $2.60
- INAB $2.30
- Resistance Level
- ELWS $3.40
- INAB $2.49
- Average True Range (ATR)
- ELWS 0.32
- INAB 0.14
- MACD
- ELWS 0.09
- INAB 0.04
- Stochastic Oscillator
- ELWS 66.13
- INAB 93.88
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.